Table IV.

Clinical efficacy outcomes per started cycle (intent-to-treat population)

	Corifollitropin alfa (n = 756)	rFSH (n = 750)	P-valuea)
Positive hCG testb), n (%)	364 (48.1)	352 (46.9)	0.64
Clinical pregnancyc), n (%)	322 (42.6)	308 (41.1)	0.57
Vital pregnancyd), n (%)	302 (39.9)	293 (39.1)	0.75
Ongoing pregnancye), n (%)	294 (38.9)	286 (38.1)	0.71
Multiple pregnancyf), n (%)	83 (28.2)	66 (23.1)	0.18
Early miscarriageg), n (%)	27 (8.4)	21 (6.8)	0.55

^a)P-values are based on Fisher's exact test, except for ongoing pregnancy where the P-value is based on the likelihood ratio test corresponding to the generalized linear model with covariates treatment group, age class (<32 years, ≥32 years) and region (Europe, North America).

^b)Positive hCG test at least 14 days after embryo transfer or USS with at least one gestational sac.

^c)Clinical pregnancy: gestational sac on USS.

^d)Vital pregnancy: gestational sac + fetal heartbeat.

^e)Ongoing pregnancy: vital fetus at least 10 weeks after embryo transfer or live birth.

^f)Per ongoing pregnancy.

^g)Per clinical pregnancy.